Denosumab (Prolia®)의 투여 간격 및 칼슘·비타민 D 복합제제 처방 여부에 따른 임상적 결과 평가
Evaluation of Clinical Outcomes by Therapeutic Dosing Interval of Denosumab (Prolia®) and Calcium-Vitamin D Prescriptions
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Denosumab (Prolia®) is administered every 6 months for osteoporosis treatment. Co-administration of calcium andvitamin D is required to minimize hypocalcemia risk. We evaluated clinical outcomes based on the administration interval ofdenosumab and co-prescription with calcium-vitamin D combination products. Methods: A retrospective study was conducted usingelectronic medical records from 668 patients who started denosumab therapy between January 1 and December 31, 2018, at SeoulNational University Bundang Hospital. Clinical outcomes, as measured by changes in T-score, were evaluated by the intervals andconcurrent prescriptions with calcium–vitamin D combination products. Results: Of the 668 patients, 333 patients met the eligibilitycriteria. These patients were divided into two groups based on appropriateness of the administration interval: “Appropriate” (304patients, 91.3%) and “Inappropriate” (29 patients, 8.3%). T-score changes were significantly higher in the “Appropriate” than in the“Inappropriate” group (0.30±0.44 vs. 0.13±0.37, p=0.048). At the beginning of the treatment, 221 patients (66.4%) were prescribedcalcium-vitamin D combination products, but the changes in T-scores were not significantly different by the prescription status of theproduct (0.29±0.46 vs. 0.28±0.38, p=0.919). Conclusion: T-scores were significantly improved in patients with appropriateadministration intervals. No significant changes in T-scores were observed by the prescription status with calcium-vitamin Dcombination products. For optimal treatment outcomes, prescribers should encourage adherence to the approved prescriptioninformation on dosage and administration, and pharmacists should provide medication counseling for patients.
Abstract
Background: Denosumab (Prolia®) is administered every 6 months for osteoporosis treatment. Co-administration of calcium andvitamin D is required to minimize hypocalcemia risk. We evaluated clinical outcomes based on the administration interval ofdenosumab and co-prescription with calcium-vitamin D combination products. Methods: A retrospective study was conducted usingelectronic medical records from 668 patients who started denosumab therapy between January 1 and December 31, 2018, at SeoulNational University Bundang Hospital. Clinical outcomes, as measured by changes in T-score, were evaluated by the intervals andconcurrent prescriptions with calcium–vitamin D combination products. Results: Of the 668 patients, 333 patients met the eligibilitycriteria. These patients were divided into two groups based on appropriateness of the administration interval: “Appropriate” (304patients, 91.3%) and “Inappropriate” (29 patients, 8.3%). T-score changes were significantly higher in the “Appropriate” than in the“Inappropriate” group (0.30±0.44 vs. 0.13±0.37, p=0.048). At the beginning of the treatment, 221 patients (66.4%) were prescribedcalcium-vitamin D combination products, but the changes in T-scores were not significantly different by the prescription status of theproduct (0.29±0.46 vs. 0.28±0.38, p=0.919). Conclusion: T-scores were significantly improved in patients with appropriateadministration intervals. No significant changes in T-scores were observed by the prescription status with calcium-vitamin Dcombination products. For optimal treatment outcomes, prescribers should encourage adherence to the approved prescriptioninformation on dosage and administration, and pharmacists should provide medication counseling for patients.
참고문헌 (20)
- "Osteoporosis and Osteoporotic Fracture Fact Sheet 2019"[URL]
- 최성훈, "Incidence and Management Trends of Osteoporotic Vertebral Compression Fractures in South Korea: A Nationwide Population-Based Study", Asian Spine Journal, 14(2), pp.220~228 (2020), 대한척추외과학회[DOI]
- Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med, 361(8), pp.756~765 (2009)
- Cummings SR, "Vertebral fractures after discontinuation of denosumab : A post hoc analysis of the randomized placebo-controlled FREEDOM trial and Its extension", J Bone Miner Res, 33(2), pp.190~198 (2018)
- Daga N, "Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency", BMJ Case Rep, 13(8), pp.e234508~ (2020)
- Nakamura Y, "Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment", Bone Res, 5, pp.17021~ (2017)
- Carroll R, "Endocrine and metabolic emergencies : hypocalcaemia", Ther Adv Endocrinol Metab, 1(1), pp.29~33 (2010)
- Camacho PM, "American Association of Clinical Endocrinologists", American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update, 2020, pp.26(1), 1~46
- Bekker PJ, "A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women", J Bone Miner Res, 19(7), pp.1059~1066 (2004)
- "Approved package insert of Prolia® Pre-filled Syringe"[URL]
- "Denosumab increasingly prescribed in osteoporosis treatment"[URL]
- Fleish H, "Bisphosphonates in bone disease", pp.30~33 (2000), Academic Press
- Bone HG, "10 years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5(7), pp.513~523 (2017)
- Bone HG, "Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass", J Clin Endocrinol Metab, 96(4), pp.972~980 (2011)
- Moran CP, "Real World Experience of Denosumab Treatment in the Belfast Osteoporosis Service", Ulster Med J, 88(3), pp.150~156 (2019)
- "Notification 2020-221"[URL]
- Lyu H, "Delayed denosumab injections and bone mineral density response : An electronic health recordbased study", J Clin Endocrinol Metab, 105(5), pp.1435~1444 (2020)
- Wong-Pack M, "The effects of noncompliance to Prolia(denosumab)on the changes in bone mineral density : A retrospective review", J Osteoporos, 2016, pp.7903128~ (2016)
- Tsvetov G, "Denosumab-induced hypocalcemia in patients with osteoporosis : can you know who will get low?", Osteoporos Int, 31(4), pp.655~665 (2020)
- Body JJ, "Hypocalcaemia in patients with metastatic bone disease treated with denosumab", Eur J Cancer, 51(13), pp.1812~1821 (2015)